What is Baseimmune?
Baseimmune is at the forefront of developing next-generation active immunotherapies by integrating advanced computational design with protein engineering. Their innovative platform crafts custom antigens to tackle the complexities of chronic diseases, offering solutions where traditional methods may fail. The company is committed to enhancing patient outcomes through bold, science-driven innovations. Their target clients include healthcare providers and organizations focused on chronic disease management.
How much funding has Baseimmune raised?
Baseimmune has raised a total of $11.3M across 1 funding round:
Series A
$11.3M
Series A (2024): $11.3M with participation from Msd
Key Investors in Baseimmune
Msd
MSD Czech Republic sro is a pharmaceutical company headquartered in Prague, Czech Republic, specializing in developing, manufacturing, and distributing pharmaceutical products and medical solutions. As part of the global MSD organization, they focus on research and innovation in healthcare, offering medications and treatments across various therapeutic areas.
What's next for Baseimmune?
The recent major strategic investment in Baseimmune signals a pivotal moment for the company, likely enabling an acceleration of its research and development pipeline. This Series A financing, characterized as enterprise-level, suggests a focus on scaling operations, expanding clinical trials, and potentially forging strategic partnerships within the healthcare and pharmaceutical industries. The company's emphasis on computational design and protein engineering for chronic diseases positions it for significant growth and impact in a market seeking novel therapeutic approaches.
See full Baseimmune company page
